REGN — AI Stock Analysis & Recommendation
TradeFlare's AI research teams rate REGN a BUY with a conviction of 40/100. The current price is $774.61.
- Entry: $790.0
- Target: $908.5
- Stop: $671.5
The setup suggests a short-term oversold bounce with longer-term fundamental strength. Catalysts to watch: Strong revenue growth driven by key products like Dupixent; Upcoming EYLEA HD launch to further bolster sales; Proprietary technology platforms supporting innovation and competitive advantage. Key risks: EYLEA facing biosimilar competition post-exclusivity; Reliance on two distributors for a significant portion of revenue; Potential pipeline execution and clinical trial risks.
FlareScore breakdown — Technical: 40 · Fundamental: 80 · Sentiment: 60 · Risk: 20
Frequently asked questions
Is REGN a buy? TradeFlare's AI currently rates REGN a BUY with 40/100 conviction.
What is the price target for REGN? TradeFlare's AI price target for REGN is $908.5.
Last updated September 18, 2026 · AI-generated analysis for informational purposes, not financial advice.